日本の乳がん治療市場：タイプ別、治療タイプ別、エンドユーザー別、地域別、機会、予測、2019年～2033年

日本の乳がん治療の市場規模は、2026年～2033年の予測期間中に8.80％のCAGRで拡大し、2025年の13億8,000万米ドルから2033年には27億1,000万米ドルに成長すると予測されています。同市場の成長は、国内における乳がん患者の増加、同市場の主要企業による新治療法の上市に向けた投資の増加、同疾患の脅威の高まりに対抗するための研究活動の重視の高まりに起因しています。Global Cancer Observatoryの推計によると、2022年、乳がんは日本の女性におけるがんの主要なタイプであり、がん患者全体の21.6%を占めました。

日本の高齢者人口の増加、効果的な治療法に対する要求の高まり、政府認可の増加、研究努力の高まりは、日本の乳がん治療市場の成長と拡大に影響を与える主な要因の一部です。一方、乳がんに関する認識を高め、早期検診を支援するための公的機関および民間団体の取り組みが活発化していることも、市場の需要を後押ししています。日本のヘルスケア制度は、公的保険の適用によりがん治療への手頃な価格とアクセスを保証することで、市場の成長をさらに後押ししています。

当レポートでは、日本の乳がん治療市場について調査し、市場の概要とともに、タイプ別、治療タイプ別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国の関税が日本の乳がん治療市場に与える影響

第4章 エグゼクティブサマリー

第5章 日本乳がん治療市場の見通し（2019年～2033年）

• 市場規模分析と予測
  • 金額別
  • タイプ別
    • 乳管内がん（DCIS）
    • 浸潤性乳管がん（IDC）
    • 上皮内小葉がん（LCIS）
    • 浸潤性小葉がん（ILC）
    • トリプルネガティブ乳がん
    • 炎症性乳がん（IBC）
    • 転移性乳がん
    • 妊娠中の乳がん
    • その他
  • 治療タイプ別
    • 手術
    • 放射線治療
    • 化学療法
    • ホルモン療法
    • 標的療法
    • 免疫療法
    • その他
  • エンドユーザー別
    • がん研究機関
    • 病院
    • 外来手術センター
    • その他
  • 地域別
    • 北部[北海道・東北]
    • 中部（関東・中部）
    • 南部[関西、中国、四国、九州・沖縄]
  • 企業別市場シェア分析（上位5社およびその他- 金額ベース、2025年）
• 2025年の市場マップ分析

第6章 需要供給分析

第7章 バリューチェーン分析

第8章 ポーターのファイブフォース分析

第9章 PESTLE分析

第10章 価格分析

第11章 市場力学

• 市場の促進要因
• 市場の課題

第12章 市場動向と発展

第13章 規制枠組みとイノベーション

• 規制当局の承認
• 臨床試験

第14章 特許の情勢

第15章 ケーススタディ

第16章 競合情勢

• 市場リーダートップ5の競合マトリックス
• 参入企業トップ5のSWOT分析
• 市場の主要企業トップ10の情勢
  • Novartis Pharma K.K.
  • Pfizer Japan Inc.
  • Eisai Co., Ltd.
  • Merck & Co., Inc.
  • Kyowa Kirin Co., Ltd.
  • Eli Lilly Japan K.K.
  • Bristol-Myers Squibb K.K.
  • AstraZeneca plc
  • Sanofi K.K.
  • Daiichi Sankyo Company, Limited

第17章 戦略的提言

第18章 調査会社について・免責事項

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Japan Breast Cancer Treatment Market, By Value, in USD Billion, FY2019-FY2033F
• Figure 2. Japan Breast Cancer Treatment Market Share (%), By Type, FY2019-FY2033F
• Figure 3. Japan Breast Cancer Treatment Market Share (%), By Treatment Type, FY2019-FY2033F
• Figure 4. Japan Breast Cancer Treatment Market Share (%), By End-User, FY2019-FY2033F
• Figure 5. Japan Breast Cancer Treatment Market Share (%), By Region, FY2019-FY2033F'
• Figure 6. By Type Map-Market Size (USD Billion) & Growth Rate (%), FY2025
• Figure 7. By Treatment Type Map-Market Size (USD Billion) & Growth Rate (%), FY2025
• Figure 8. By End-User Map-Market Size (USD Billion) & Growth Rate (%), FY2025
• Figure 9. By Region Map-Market Size (USD Billion) & Growth Rate (%), FY2025

Japan breast cancer treatment market is projected to witness a CAGR of 8.80% during the forecast period FY2026-FY2033, growing from USD 1.38 billion in FY2025 to USD 2.71 billion in FY2033. The market's growth can be attributed to the increasing cases of breast cancer in the country, rising investments by the key players of the market towards the launch of new therapies, and growing emphasis on research activities to combat the rising threat of the condition. As per the estimates of the Global Cancer Observatory, breast cancer was the leading type of cancer in women in Japan in 2022, accounting for 21.6% of all cancer cases.

The growth of the country's geriatric population, rising requirement for effective therapies, increasing government approvals, and rising research efforts are some of the major factors influencing the growth and expansion of the breast cancer treatment market in Japan. Meanwhile, the rising efforts of both public and private organizations to promote awareness about breast cancer and support early screening are also bolstering the market demand. The country's healthcare system is further supporting market growth by ensuring the affordability and accessibility of cancer therapies through public insurance coverage.

Increasing Research Activities Support Market Expansion

Rising research activities by leading research centers and educational institutions across the country are positively influencing the market's expansion by bolstering the availability of novel therapeutic solutions. The research ecosystem is also accelerating the introduction of advanced surgical techniques and drugs that allow oncologists to improve treatment outcomes and enhance patient experience. For instance, in February 2024, researchers at Tohoku University announced that they had developed a novel monoclonal antibody that targets HER2-positive breast cancer cells. The antibody represents a significant advancement in breast cancer treatment as well as a promise for the availability of less toxic and more effective treatment options, as the antibody offers a more selective and targeted approach as compared to conventional treatment options, including chemotherapy.

Technological Advancements Boost Market Growth

Increasing emphasis on technological advancements are significantly driving the growth of the market by improving diagnosis, expanding the availability of therapeutic solutions, and enabling precision medicine. Artificial intelligence and machine learning are enhancing the accuracy and speed of breast cancer detection through advanced imaging and mammography, resulting in the diagnosis of the condition in a time efficient manner. Additionally, the integration of multi-gene panel tests and genomic medicine has facilitated the development and adoption of targeted therapies, allowing clinicians to tailor the treatments according to the genetic profile of the patient.

Meanwhile, innovative treatment solutions launched by leading research organizations in the country are revolutionizing cancer care. For instance, in June 2023, a team of researchers from Hiromitsu Haba at the RIKEN Nishina Center for Accelerator-Based Science (RNC) and RIKEN Cluster for Pioneering Research (CPR) in Japan developed a new technique that offers less harmful and more precise alternatives to currently available treatments. As clinical trials progress for the technique, it is expected to attract more investments and propel advancements in breast cancer treatment, allowing the country to offer innovative oncology solutions to its patient population.

Targeted Therapies Hold Major Market Share

The segment's dominance can be attributed to the higher efficacy and safety of targeted therapies and their ability to address specific genetic mutations in cancer cells. The rapid advancements in companion diagnostics and the adoption of precision medicine are further enabling physicians to match targeted therapies to the unique genetic profiles of the patients, improving their effectiveness. Additionally, a wide number of targeted therapies are also receiving approval in Japan. For instance, in March 2024, AstraZeneca plc received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for Truqap (capivasertib) plus Faslodex (fulvestrant) for breast cancer. The company received approval for the recurrent or unresectable AKT serine/threonine kinase 1 or phosphatase, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, and tensin homolog-altered hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer. The drug combination is intended for adult patients who have progressed following endocrine therapy. The approval is based on the data collected from the double-blind, randomized, global CAPItello-291 Phase III clinical trial.

Impact of the U.S. Tariff on Japan Breast Cancer Treatment Market

The tariffs are expected to bolster the costs for advanced equipment such as biopsy devices and mammography machines, potentially affecting the accessibility and affordability of early breast cancer detection technologies.

Various healthcare institutions may face budget issues and financial strain, limiting their ability to acquire new equipment and therapeutic solutions, thus impacting the quality of care provided to the patient population.

Meanwhile, the tariffs are expected to encourage domestic manufacturers to focus on product innovation and production, reducing their reliance on imports and mitigating the adverse effects associated with the evolution of trade policies.

Key Players Landscape and Outlook

The key players of the market are focusing on investing in product innovations and launching new drugs in the country. For instance, in December 2024, Daiichi Sankyo Company, Limited received approval from Japan's MHLW for its trophoblast cell surface antigen 2 (Trop2)-directed antibody-drug conjugate (ADC) for treating adults with hormone receptor (HR)-positive, HER2-negative recurrent or unresectable breast cancer after prior chemotherapy. This approval expands the therapeutic solutions available for advanced stages of breast cancer and is encouraging a wider adoption of ADCs. Such launches are providing improved efficacy and safety as compared to conventional treatment solutions, positively influencing the market's expansion.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariff on Japan Breast Cancer Treatment Market

4. Executive Summary

5. Japan Breast Cancer Treatment Market Outlook, FY2019-FY2033F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Type
    • 5.2.1.1. Ductal Carcinoma In Situ (DCIS)
    • 5.2.1.2. Invasive Ductal Carcinoma (IDC)
    • 5.2.1.3. Lobular Carcinoma In Situ (LCIS)
    • 5.2.1.4. Invasive Lobular Cancer (ILC)
    • 5.2.1.5. Triple Negative Breast Cancer
    • 5.2.1.6. Inflammatory Breast Cancer (IBC)
    • 5.2.1.7. Metastatic Breast Cancer
    • 5.2.1.8. Breast Cancer During Pregnancy
    • 5.2.1.9. Other Types
  • 5.2.2. By Treatment Type
    • 5.2.2.1. Surgery
    • 5.2.2.2. Radiation Therapy
    • 5.2.2.3. Chemotherapy
    • 5.2.2.4. Hormonal Therapy
      • 5.2.2.4.1. Selective Estrogen Receptor Modulators
      • 5.2.2.4.2. Aromatase Inhibitors
      • 5.2.2.4.3. Estrogen Receptor Downregulators
    • 5.2.2.5. Targeted Therapy
      • 5.2.2.5.1. Abemaciclib
      • 5.2.2.5.2. Adotrastuzumab Emtansine
      • 5.2.2.5.3. Everolimus
      • 5.2.2.5.4. Trastuzumab
      • 5.2.2.5.5. Ribociclib
      • 5.2.2.5.6. Palbocicib
      • 5.2.2.5.7. Pertuzumab
      • 5.2.2.5.8. Olaparib
      • 5.2.2.5.9. Others
    • 5.2.2.6. Immunotherapy
    • 5.2.2.7. Others
  • 5.2.3. By End-user
    • 5.2.3.1. Cancer Research Institutes
    • 5.2.3.2. Hospitals
    • 5.2.3.3. Ambulatory Surgical Centers
    • 5.2.3.4. Others
  • 5.2.4. By Region
    • 5.2.4.1. North [Hokkaido and Tohoku]
    • 5.2.4.2. Central [Kanto and Chubu]
    • 5.2.4.3. South [Kansai, Chugoku, Shikoku, and Kyushu & Okinawa]
  • 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2025)
• 5.3. Market Map Analysis, FY2025
  • 5.3.1. By Type
  • 5.3.2. By Treatment Type
  • 5.3.3. By End-user
  • 5.3.4. By Region

6. Demand Supply Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

• 11.1. Market Drivers
• 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

• 13.1. Regulatory Approvals
• 13.2. Clinical Trials

14. Patent Landscape

15. Case Studies

16. Competitive Landscape

• 16.1. Competition Matrix of Top 5 Market Leaders
• 16.2. SWOT Analysis for Top 5 Players
• 16.3. Key Players Landscape for Top 10 Market Players
  • 16.3.1. Novartis Pharma K.K.
    • 16.3.1.1. Company Details
    • 16.3.1.2. Key Management Personnel
    • 16.3.1.3. Products and Services
    • 16.3.1.4. Financials (As Reported)
    • 16.3.1.5. Key Market Focus and Geographical Presence
    • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 16.3.2. Pfizer Japan Inc.
  • 16.3.3. Eisai Co., Ltd.
  • 16.3.4. Merck & Co., Inc.
  • 16.3.5. Kyowa Kirin Co., Ltd.
  • 16.3.6. Eli Lilly Japan K.K.
  • 16.3.7. Bristol-Myers Squibb K.K.
  • 16.3.8. AstraZeneca plc
  • 16.3.9. Sanofi K.K.
  • 16.3.10. Daiichi Sankyo Company, Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer